Mirum Pharmaceuticals (MIRM) has shown strong revenue growth, with Q4 revenue of $99.41 million, exceeding estimates. The company expects significant growth in 2025, with projected sales between $420 million and $435 million, indicating continued momentum. However, the stock recently fell 4.4% after missing earnings expectations, despite positive guidance.
The stock is currently oversold, with an RSI of 39.26, suggesting a potential rebound. It is trading near the lower Bollinger Band, indicating possible support. The MACD is bearish, but the pre-market rise of 2.09% could signal short-term positivity.
Analysts maintain a Strong Buy rating with a target of $65.29, reflecting confidence. However, insider selling activity is a concern. The stock is near Fibonacci support at 42.51, with resistance at 47.03.
Based on the analysis, MIRM is expected to rise to $46.50 next week. However, considering the overall bearish trend, it is advisable to sell into this rally rather than holding for further gains.
The price of MIRM is predicted to go up -6.64%, based on the high correlation periods with PRO. The similarity of these two price pattern on the periods is 96.86%.
MIRM
PRO
Citigroup
2024-11-13
Price Target
$65 → $68
Upside
+54.83%
Baird
2024-11-13
Price Target
$44 → $50
Upside
+13.84%
Leerink Partners
2024-10-17
Price Target
$47 → $49
Upside
+24.62%